Kathmandu, March 18:

Pharma major Ranbaxy Laboratories today launched the first-of-its-kind natural and probiotic drug for dental diseases in India and Nepal.

According to the company, the exclusive in-licensing agreement for marketing the drug, Inersan, has been signed with CD Pharma, a subsidiary of the US-based VSL Pharmaceuticals. The drug is used for the treatment of dental problems like periodontitis, gingivitis and halitosis. Ranbaxy claimed that at present there was no drug available for the treatment of such dental problems and Inersan will be the first-of-its-kind to be introduced in India and Nepal.

According to a press release, early-stage periodontitis (gum disease) is painful causing swelling and bleeding in gums. The disease usually leads to serious infection and loss of tooth. Dentists normally recommend surgical options such as flap surgery, soft tissue grafting or bone grafting and guided tissue regeneration.

Sanjeev I Dani, senior vice-president and regional director Asia and CIS, Ranbaxy, said, “Periodontitis, gingivitis and halitosis are common dental problems which if ignored, can lead to more serious complications.”